Patients with sarcoidosis undergo spontaneous remission or may be effectively controlled with glucocorticoids alone in many cases. Progressive and refractory pulmonary sarcoidoisis constitute >10% of the patients seen at specialized centers. Pulmonary fibrosis and associated complications, such as infections and pulmonary hypertension, are leading causes of mortality. No universal definition of refractoriness exists; we therefore propose classifying patients as having refractory disease when the following criteria are fulfilled: (1) progressive disease despite at least 10 mg of prednisolone or equivalent for at least 3 months and the need for additional disease-modifying antisarcoid drugs due to a lack of efficacy, drug toxicity, or intolerability; and (2) treatment started for significant impairment of life due to progressive pulmonary symptoms. Both criteria should be fulfilled. Treatment options in addition to or instead of glucocorticoids for these patients include second-line (methotrexate, azathioprine, leflunomide) and third-line agents (infliximab, adalimumab). Other immunmodulating agents can be used, but the evidence is very limited. Newer agents with antifibrotic properties, such as pirfenidone or nintedanib, might also hold promise for the pulmonary fibrosis seen in sarcoidosis. Treating physicians have to actively look for potentially treatable complications, such as pulmonary hypertension, cardiac disease, or infections before patients are classified as treatment-refractory. Ultimately, lung transplantation has to be considered as a treatment option for patients not responding to medical therapy. In this review, we aim to propose a new definition of refractoriness, describe the associated clinical features, and suggest the therapeutic approach.
S arcoidosis is a multisystem disease characterized by the presence of noncaseating granulomas that affects the lungs in over 90% of the patients. 1 The disease pathogenesis has not been elucidated completely. However, our current understanding is that it likely includes exposure to one or more, possibly airborne, antigens (bacterial, organic, inorganic), which then trigger an abnormal immune response in a genetically predisposed host. 2 About two thirds of the patients will undergo remission within several months to a few years, whereas about one third will require short-term or long-term treatment. 1 The intriguing observations of chest radiographs in sarcoidosis published by Scadding in 1961 3 are still considered as the gold standard because of the limited use of radiation and its association with resolution or progression of the disease. However, the interobserver variability and a lack of association with functional clinical parameters [eg, pulmonary function tests (PFTs), 6-min walk test] are limiting factors. 4 Computed chest tomography (CT) has been found to be useful in distinguishing areas of potentially reversible lung damage from areas of presumed fibrotic lung. 4 Even more importantly, a chest CT with or without contrast often allows for the identification of mediastinal or hilar adenopathy, allowing for a potential diagnosis of sarcoidosis through endobronchial ultrasound-guided transbronchial needle aspiration. It thereby prevents the need for mediastinoscopy in as many as 87% of the patients. 5 Especially in patients with parenchymal disease and with a higher risk for complications, such as pneumothorax, endobronchial ultrasound alone may yield a diagnosis and obviate the need for transbronchial biopsies. 6 Treatment recommendations exist for pulmonary and extrapulmonary manifestations of sarcoidosis [7] [8] [9] [10] ; however, the available evidence to guide treatment is limited. Therapeutic options include first-line (glucocorticoids), second-line [disease-modifying antisarcoid drugs (DMASD)], and thirdline (biological agents) therapies. Treatment should always be tailored to the individual patient and adapted to the presence or the absence of clinical symptoms or the worsening of objective functional parameters, such as PFTs.
Refractory disease has not been universally defined, and treatment recommendations are not existent for this, albeit small, group of patients. In addition, it is challenging to define refractory disease with no approved therapies other than glucocorticoids (and Acthar gel, which has been approved on the basis of very limited evidence) by the US Food and Drug Administration (FDA) and because of the systemic nature of the disease. In specialized centers, refractory or progressive patients can nevertheless constitute a significant proportion of all patients. In a survey from a World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) Task Force, >10% of the patients required an increase in systemic medication 5 years after the initial diagnosis. 11 Data from the "a case control etiologic study of sarcoidosis (ACCESS)" revealed that among all characteristics of the included patients, dyspnea and the need for initial systemic therapy were associated with systemic therapy at 2 years of follow-up. 12 In addition, organ involvement is different according to the race, the sex, and the age. African Americans, for example, tend to have more skin involvement (other than erythema nodosum), hematological abnormalities, and lymph node, liver, and bone marrow affection. 13 However, it is important to note that organ involvement per se does not necessarily translate into chronicity or refractoriness.
Also, it is clear that refractory sarcoidosis often includes significant fibrosis. Fibrotic sarcoidosis is associated with increased mortality. 14, 15 Patients in this group die not only from the progression of their inflammatory disease, but also from complications of the fibrosis, including pulmonary hypertension (PH) and infections. 15 The overlapping, but nevertheless different concept of "advanced pulmonary sarcoidosis," has evolved over the last couple of years. 16 Advanced pulmonary sarcoidosis includes fibrocystic changes with either airflow limitation or severe restrictive impairment and can harbor active or inactive lesions [as evidenced by 18 F-positron emission-CT (PET-CT)]. The associated complications include chronic respiratory insufficiency, PH, pulmonary aspergillosis, or other infections. 16 Acute worsening events are frequent with a median of 3 episodes per year. 17 Advanced pulmonary sarcoidosis may be a potential cause of treatment-refractory disease and the aforementioned complications have to be actively looked for.
In this review, we aim to define treatment-refractory disease, propose clinical and functional parameters associated with refractoriness, and, ultimately, suggest a step-wise approach for the management of refractory patients.
METHODS AND THE SEARCH STRATEGY
PubMed and Google scholar were searched using the terms "refractory sarcoidosis," "progressive sarcoidosis," and combinations of "sarcoidosis," and "methotrexate, azathioprine, leflunomide, rituximab, infliximab, and adalimumab." Articles were reviewed by abstract and included when deemed appropriate by at least 2 authors. Additional references were identified from the included articles and personal archives of the authors. Reviews, case series, and clinical studies published in peer-reviewed journals were included. Articles published in English, Spanish, and German were included for analysis. Non-English language articles were reviewed and translated by 1 author (P.K.) and their content was discussed with at least one other author (K.S., R.P.B., or N.J.S.). These articles were also included when at least 2 authors agreed upon their appropriateness.
DEFINITION OF REFRACTORY PULMONARY SARCOIDOSIS
In our article, we strive to characterize the term refractory (ie, treatment-refractory) pulmonary sarcoidosis. As of yet, no universally accepted definition of refractory pulmonary sarcoidosis exists. However, patients with progressive disease, despite adequate therapy consisting of corticosteroids, are commonly referred to as having refractory disease according to the literature. 18 Although corticosteroids remain the first line of treatment and are being used as such, no validated protocol exists with regard to the dosage or the treatment duration, thereby complicating what is to be considered as treatmentrefractory. 1, 19, 20 A systematic review from 2005 found that dosages vary widely and that no clear evidence of benefit exists beyond 2 years of treatment. 21 Indications for therapy, response, and thereby the optimal treatment duration are especially difficult to measure when looking at the quality of life rather than objective evidence of organ dysfunction.
However, validated questionnaires exist (eg, the Sarcoidosis Health Questionnaire and Fatigue Assessment Scale) and guidelines on their use have been published. 22 Factors confounding the assessment of response to therapy are coexistence of other diseases or complications due to immunosuppressive therapy. It becomes clear that along with the question on how to define refractory sarcoidosis, one must aim to answer questions about what the optimal dose and duration of a treatment ought to be and how to assess its response.
In light of this complex background, we propose the following definition of refractory pulmonary sarcoidosis: (1) Progressive pulmonary disease despite glucocorticosteroid therapy at an adequate dosage defined as at least 10 mg of prednisone 23 once a day and a duration of therapy of at least 3 months after initial dosages of 20 to 40 mg/d for 1 to 3 months and the need for additional therapy due to a lack of efficacy, glucocorticoid toxicity, or severe side effects. (2) Treatment started for impaired quality of life due to progressive pulmonary symptoms with or without additional disease manifestations (eg, disfiguring disease, neurosarcoidosis, etc.).
To be considered as treatment-refractory, pulmonary disease patients should fulfill both criteria, and other causes such as pulmonary arterial hypertension (PAH), infection, or cardiac sarcoidosis have to be excluded. This definition is based on similar descriptions of refractory pulmonary sarcoidosis in the literature and aims to simplify the approach to any given patient. In addition, it is the authors' personal experience, and by no means a recommendation that is based on solid evidence, that patients fulfilling these criteria are those who are usually more difficult to treat in clinical practice. Although there are no standardized endpoints to define refractoriness, it is the authors' intention to propose a definition that serves clinicians as a guideline on when to intensify treatment. Clearly, this definition has to be validated in well-designed clinical trials.
FEATURES ASSOCIATED WITH REFRACTORY DISEASE
As many as 10% of the patients undergoing treatment for sarcoidosis will continue to have active disease. 18 Most deaths from sarcoidosis in the western hemisphere occur because of advanced pulmonary fibrosis with PAH and less commonly cardiac, central nervous system, and hepatic involvement. 24, 25 This contrasts with reports from Japan, citing cardiac complications as the cause of death in 77% to 85% of the sarcoidosis-related deaths as recently reviewed by Lynch et al. 26 Given the high rate of pulmonary involvement and the potential of progression to end-stage fibrosis, we will focus our review on the diagnosis of pulmonary refractory sarcoidosis and describe clinical findings that could constitute refractoriness (Table 1 ). Finally, we will propose a diagnostic and therapeutic algorithm for refractory pulmonary sarcoidosis patients ( Fig. 1 ).
Clinical Symptoms
Symptoms of mediastinal-pulmonary sarcoidosis can encompass a large range of clinical findings. The most common symptom is a persistent cough, followed by dyspnea (which is rare early in the disease course) and rarely chest pain, wheezing, or hemoptysis. Crackles on examination are rare and correlate with changes of fibrosis. The variety in clinical symptoms is mirrored in the wide range of histopathologic and radiographic presentations. However, these objective and subjective data do not always correlate.
Patients considered to have refractory disease will typically have a persistent symptomatology (dyspnea, cough, etc.) despite an adequate therapeutic trial with glucocorticoids (see definition above). Sarcoidosis patients who respond well to higher (20 to 40 mg/d) glucocorticoid doses at first but have recurrent symptoms upon reduction to targeted doses of <10 mg/d after 3 months will also be candidates for the introduction of a secondline agent and thus meet the definition of "treatment-refractory." The presence of additional progressive extrapulmonary symptoms requiring immunosuppressive treatment in a situation of stable pulmonary disease would also constitute systemic refractory sarcoidoisis stratified by the index organ involved.
Noninvasive Testing (Pulmonary Function Testing and 6-Min Walk Distance)
There is no diagnostic pattern in PFTs, and the volume of forced vital capacity (FVC) does not correlate clinically with symptoms of dyspnea. 27 The most prevalent pattern of PFTs in patients with sarcoidosis is restrictive. 28, 29 Obstruction can nevertheless also be present, either in isolation or concomitantly. [30] [31] [32] This correlates with the histopathologic pattern of sarcoidosis involving either the lung parenchyma or the airways, or both. Obstruction in sarcoidosis may be less responsive to immunosuppressive therapy 33 and can be a significant source of refractory disease. In sarcoidosis, there is no definite consensus on how to follow changes in FVC in response to treatment. 34 In idiopathic pulmonary fibrosis (IPF), it was shown that a decline of Z5% was associated with an increase in mortality 35 and a decline of 2% to 6% has been found to represent the minimal clinically important difference. 36 Although these thresholds may not necessarily hold true for sarcoidosis, we suggest that in the absence of better data, a decline of Z5% (absolute change of predicted) FVC is consistent with refractoriness in sarcoidosis patients. The caveat to this approach is the test variability and the impact of obesity and the long-term use of glucocorticosteroids as well as the presence or the absence of sleep apnea on testing. Our unpublished data suggest that a significant reduction in diffusing capacity of the lung for carbon monoxide may indicate refractory pulmonary disease in the absence of PAH as a cause of the decrease in diffusing capacity of the lung for carbon monoxide.
The 6-minute walk distance (6MWD) is an established measurement for many pulmonary conditions. Although sarcoidosis is not listed as an indication for testing by the American Thoracic Society, 37 it has nevertheless been used in this population. 28 Although results (improvement or a lack of improvement) have been mixed in clinical trials that incorporated it as an outcome measure, refractory patients should either have declining values as compared with baseline or an increase only with supplemental oxygen. One has to keep in mind, however, that the 6MWD is influenced by multiple factors, making it difficult to discriminate the cause of declining values in some cases. 28 The Role of Imaging in Refractory Pulmonary Sarcoidosis Many patients who respond readily to glucocorticoid treatment alone may never need advanced imaging in addition to conventional chest radiographs. Patients who have persisting or worsening clinical symptoms and functional findings despite adequate treatment will require chest CT or other imaging modalities.
Studies that evaluated the CT features that are associated with sarcoidosis aimed to differentiate reversible features such as nodules or peribronchovascular thickening from findings of potentially irreversible damage such as honeycombing, bronchial distortion, or bullae. 30, 34 Before intensifying therapy in a patient nonresponsive to corticosteroids, we recommend evaluating for CT scan findings suggestive of end-stage fibrosis, possibly followed by a PET scan to screen for sites of active inflammation. The suspicion of fibrotic changes would be supported by stable PFTs over several years. 38 CT is also the most important imaging modality to assess for complications of advanced pulmonary sarcoidosis, such as aspergilloma, PH, or obstruction. 4 In a recent study, Walsh et al 14 applied a staging system combining fibrosis grading in highresolution CT and the composite physiological index to a sarcoidosis population. This staging system was found to be predictive of mortality and could easily be used by radiologists and clinicians likewise.
A newer imaging modality correlating with inflammatory activity is 18 F-FDG-PET. It may especially predict the worsening of pulmonary involvement and show areas of active disease involvement, expected to improve with treatment. Not all insurances cover 18 F-FDG-PET in sarcoidosis. 39-43 18 F-FDG-PET has been shown to demonstrate active inflammation even in stage IV chest radiography, thereby being a useful marker of active disease and potential response to therapy. 42 All patients suspected of having refractory pulmonary sarcoidosis should receive imaging by CT assessing for reversible/irreversible including clinicoradiologic staging as proposed by Walsh and colleagues. If irreversible features are identified, we suggest the consideration of 18 F-PET-CT to look for active lesions that could be amenable to treatment. If no active lesions are identified, complications need to be addressed and treated. Nevertheless, even in inactive sarcoidosis by imaging, a therapeutic trial with second-line agents might be justified for individual patients. Prospective validation studies are required to evaluate the role of CT and PET in predicting the need for aggressive therapy in refractory disease.
BIOMARKERS
Biomarkers as a measurement of disease activity have not yet been incorporated in clinical practice, but are being investigated. Examples include soluble interleukin-2 receptor (sIL2-R), chitotriosidase, and exhaled neopterin. 44 Angiotensin-converting enzyme (ACE) has not been found to correlate reliably with the disease activity, 45 which might be due to different genotypes influencing ACE levels. 46 Furthermore, treatment with corticosteroids influences ACE levels. Nevertheless, serial measurements of ACE and sIL2-R levels were found to be useful in individual patients to monitor treatment effects. 47 Interestingly, the measurement of serum amyloid has been found to correlate with the disease activity in pulmonary sarcoidosis. 48 However, its current use in clinical practice cannot yet be recommended. In an interesting study with a small sample size, an unbiased 20-gene signature was found to be superior to a more restrictive 31-gene T-cell receptor signaling profile in the peripheral blood to distinguish complicated from uncomplicated sarcoidosis. 49 Complicated sarcoidosis in this study was defined as cardiac, neurological, or severe pulmonary sarcoidosis. The fact that the T-cell receptor signaling-centered gene expression profile was inferior compared with the gene signature derived from genomewide peripheral blood gene expression analysis underlines the fact that the pathogenesis of sarcoidosis might be T-cell driven, but refractoriness might involve more complex mechanisms. 49 In summary, we recommend serial measurements of ACE and/ or sIL2-R at baseline and to monitor the treatment response when baseline levels were elevated.
Additional biomarkers are under investigation. Peripheral blood lymphocytopenia has been found to correlate with the severity of disease manifestations, including pulmonary sarcoidosis. 50 In addition, C-reactive protein levels have been found to indicate a more severely affected subgroup of patients. Interestingly, these patients may have better responses to infliximab when this treatment in indicated. 51 Experimental studies identified additional cytokines that might be important in the disease pathogenesis and different phenotypes. Interleukin (IL)-7 (increased) and IL-5 (decreased) have been found to be altered compared with healthy controls. IL-5 was significantly more decreased in nonfibrotic pulmonary sarcoidosis patients; IL-7 was increased in the fibrotic phenotype, but not statistically significant. 52 Although still experimental, these results might identify different phenotypic subsets of sarcoidosis patients. All these biomarkers, however, still have to be validated in translational clinical studies and have not been established in clinical practice as of yet. To conclude, patients with refractory disease are characterized by persisting or worsening clinical symptoms, a decline of PFT despite treatment, and/or worsening of findings on imaging or changes from potentially reversible to irreversible features despite adequate doses of glucocorticoid treatment, keeping in mind that the adequate dose has been defined on the basis of expert opinion and consensus rather than convincing evidence from clinical studies. No universal biomarkers that are useful in terms of diagnosis or response to treatment have been defined. ACE and sIL2-R are the most frequently used, given that their levels are increased at baseline.
Our proposed diagnostic approach is depicted in the upper part of Figure 1 and the clinical/investigational findings associated with refractoriness are presented in Table 1 . In the next section, we will describe our therapeutic approach for patients with refractory disease.
THERAPEUTIC OPTIONS IN REFRACTORY SARCOIDOSIS
Glucocorticosteroids in doses ranging from 20 to 40 mg/d are the mainstay of treatment and effective in the majority of the sarcoidosis patients with possible tapering to a maintenance dose of <10 mg/d within a few months. Acthar gel, an ACTHanalog and FDA-approved medication, is not used routinely by sarcoidologists, as the evidence base is weak, but studies are ongoing to investigate its role in chronic pulmonary sarcoidosis (NCT 02188017). The clinician, often a pulmonologist or a rheumatologist, will nevertheless encounter patients who do not readily respond to glucocorticoids treatment and are therefore considered treatment-refractory.
We will focus the following section on additional secondline and third-line therapeutic agents to be considered in patients with refractory pulmonary sarcoidosis. The therapeutic approach to refractory sarcoidosis is summarized in the lower part of Figure 1 .
Second-line Disease-modifying Antisarcoid Drugs
The evidence for using these agents including methotrexate (MTX), azathioprine (AZA), leflunomide (LEF), cyclosporine (CYA), antimalarials [hydroxychloroquine (HCQ) and chloroquine (CHQ)], and mycophenolate mofetil (MMF) is astonishingly low grade. Nevertheless, many physicians treating sarcoidosis patients have gained experience using these agents. The choice of which one to use depends on the physician's preference and the predominant organ involvement rather than objective evidence. We will summarize the existing evidence and our personal experience with the use of nonsteroidal agents. Table 2 gives an overview of the specific dose and monitoring recommendations.
MTX is typically the first steroid-sparing agent used in sarcoidosis and its first reported use in a refractory sarcoidosis patient can be found in the literature as early as 1968. 53 Evidence for MTX use derives from 1 randomized double-blind placebocontrolled trial 54 and a few open-label clinical trials; [55] [56] [57] [58] additional case series or singular case reports can be found numerously in the literature. In most studies, its use was associated with a possible dose reduction of glucocorticoids and/or improvement in PFTs. In 2013, the WASOG has published recommendations for the use of MTX in sarcoidosis. 59 The risk of hypersensitivity pneumonitis in sarcoidosis seems to be lower than in patients with rheumatoid arthritis, in which this side effect is estimated to occur in up to 5% of the patients. 7 In summary, the usual starting dose ranges from 5 to 15 mg/wk with supplementation of folic acid of at least 5 mg/wk.
AZA has been studied only in open-label clinical trials 57, 60, 61 and in 1 retrospective analysis 62 with mixed results. The open-label trials showed small improvements in the forced vital capacity in a limited number of patients and steroidsparing capacities and/or disease regression in 54% of the cases in 1 study. 57 The retrospective analysis compared MTX with AZA and found similar clinical benefits (prednisone dose reduction, improvement of forced expiratory volume in one second, and vital capacity) but more infectious complications with AZA. 62 This important study provides evidence for the efficacy of both MTX and AZA in a larger number of patients in terms of the steroid-sparing capacity and clinical improvement.
LEF has been studied in pulmonary (and extrapulmonary) sarcoidosis in 2 open-label trials 63, 64 and has shown steroidsapring properties at a standard dose of 20 mg/d. In 1 study, it improved the FVC. Gastrointestinal side effects (nausea and diarrhea) and elevation of hepatic enzymes were the most common side effects. In our experience, loading with LEF (100 mg on 3 consecutive days) is usually not necessary. LEF can, however, cause interstitial lung disease. In a systematic review by Raj and Nugent, 65 interstitial lung disease caused by LEF was found most often within the first 3 months after initiation; the most common findings were bilateral ground glass opacities on chest CT and diffuse alveolar damage on histopathologic examination.
Other second-line agents are less commonly used according to the literature. MMF has not been studied in detail in sarcoidosis. The first use in a sarcoidosis patient with refractory uveitis appeared in a paper published in the Lancet in 1998. 66 MMF has shown efficacy in severe cutaneous sarcoidosis in a case series reported by Kouba et al in 2003 . 67 In addition, there are few reports on its use for renal sarcoidosis. 68 In a retrospective study of 37 patients with pulmonary sarcoidosis, MMF did not improve PFTs, but was steroid-sparing in some patients. 69 Its role for pulmonary sarcoidosis is therefore not clear until now.
The antimalarials HCQ and CHQ are thought to modulate the immune response through the inhibition of toll-like receptors 7 and 9. 70 There are limited data for their use in pulmonary sarcoidosis. In 1 randomized trial, maintenance therapy with CHQ was associated with a slower deterioration of PFTs and fewer relapses. 71 In a recent analysis, it was confirmed that the risk of retinopathy with prolonged use is higher depending on the cumulative dose. 72 A dosage of HCQ of <5 mg/kg actual body weight should be used and ophthalmologic evaluation at baseline and annually after 5 years is considered mandatory with their use. 73 
THIRD-LINE BIOLOGICAL AGENTS
Experimental evidence and limited clinical studies suggest that influencing the abnormal immune response in sarcoidosis by biological agents might be useful in certain patients. However, one has to note that the results from clinical trials with different tumor necrosis factor-a blockers are conflicting despite a clear rationale. Data are available for the tumor necrosis factor a-blockers infliximab, adalimumab, etanercept, and golimumab, the B-cell-depleting agent rituximab, and the IL12/23-antagonist ustekinumab. Additional immunmodulatory drugs, such as thalidomide, pentoxifylline, and apremilast, are considered experimental and their role is yet to be defined. Data on biological and experimental agents were reviewed recently 7,9 ; we will therefore focus this section on agents investigated in refractory pulmonary sarcoidosis.
Infliximab is the best studied biological agent in sarcoidosis. Over the last 10 years, its efficacy has been reported in numerous case reports and retrospective studies of patients with severe pulmonary and extrapulmonary disease. However, there are only 2 prospective, double-blind placebo-controlled randomized clinical trials for pulmonary sarcoidosis. 74, 75 These trials involved 138 and 19 patients, respectively, with chronic pulmonary disease despite glucocorticoid therapy. Infliximab led to improvement in the FVC and radiographical progression 74 or FVC alone. 75 In addition, we found that patients with elevated C-reactive protein levels seemed to benefit more from the intervention. 51 Of note, the beneficial effects of infliximab for extrapulmonary sarcoidosis, including neurosarcoidosis, have been described in the literature despite the absence of higher quality clinical trials, which are difficult to perform due to the very varied clinical presentations. In patients requiring prednisone doses >15 to 20 mg, infliximab has not been shown to improve the difference in FVC after 2 years of treatment. 76 Adalimumab is an alternative option, and experiences derived from larger case series as well as results from openlabel clinical trials are encouraging. We recently published an open-label clinical trial 77 that involved 11 patients with refractory sarcoidosis. Treatment success was defined as improvements in FVC, 6MWD, the Borg dyspnea score, or possible reduction of concomitant medication. After 24 and 52 weeks, 9/11 (82%) and 8/11 (80%) had improved in at least one of the variables tested. Of practical importance, the dose used in this trial was 40 mg weekly, which is higher than the standard dose of 40 mg every other week approved by the FDA for rheumatoid arthritis.
WASOG provides recommendations for the use of the tumor necrosis factor (TNF)-blockers infliximab and adalimumab in sarcoidosis; these are, however, based on the limited data available and the expert opinion of leading sarcoidologists. 78 Recommendations regarding dosage (see also Table 2) , discontinuation, and general recommendations for the use of anti-TNF a-blockers were formulated. The trial for progressive pulmonary sarcoidosis including etanercept, a soluble TNF receptor, was terminated prematurely due to ineffectiveness. 79 However, occasional case reports have also noted the efficacy for diverse disease manifestations. 80 A recent trial involving ustekinumab, a combined anti-IL12/23 antibody, and golimumab, a TNF a-blocker, was designed to assess the clinical benefits in pulmonary and cutaneous sarcoidosis. 81 The primary endpoint, improvement of change in the predicted percentage of FVC, was not reached. There was a tendency of golimumab to improve some of the cutaneous manifestations of sarcoidosis, but this did not reach statistical significance either.
Ultimately, rituximab, a monoclonal antibody directed against CD20-positive B cells, which is used in malignancies and many autoimmune diseases (including rheumatoid arthritis, vasculitis, refractory systemic lupus erythematosus, primary Sjögren syndrome among many others) was reported as salvage treatment in cases of refractory disease. It was demonstrated that, despite being a predominantly T-cell-mediated disease, B-cell depletion might still be useful in sarcoidosis patients. In a recent study including 42 patients with sarcoidosis, almost 30% (n = 12) of the patients showed positive serum titers of antinuclear antibodies when compared with healthy volunteers. 82 We recently reported a phase I/II clinical trial 83 of 10 patients with refractory pulmonary sarcoidosis, which showed improvements in FVC of >5% in 1 patient and >10% in 4 patients after 24 weeks. 6MWD improved in 5 of 10 patients after 24 weeks. Thus, there were some patients with improvements, whereas others did not benefit. No clear recommendation can therefore be given for the optimal subgroup of patients most likely to benefit from rituximab treatment.
Importantly, treating physicians not familiar with the use of anti-TNF therapies have to keep in mind that autoimmune reactions to these agents can, albeit rarely, occur. The induction of antinuclear antibodies is common, but clinically apparent systemic lupus erythematosus, demyelinating disorders, and also sarcoidosis have been reported. 84 The development of antidrug antibodies can occur, which might be prevented using a combination therapy with low-dose MTX or other DMASDs.
OTHER TREATMENTS
Optimal treatment of refractory sarcoidosis not only consists of medical treatment of the disease with second-line and third-line agents (see above), but also needs to address complications of fibrotic lung disease, such as infections (eg, aspergilloma), bronchiectasis, and PH. Physical therapies including pulmonary rehabilitation and physical training programs might improve the quality of life and maintain functional parameters despite disease progression. 85, 86 Ultimately, lung transplantation has to be considered as an option for the most severely affected patients, and early referral to the transplant team should be considered in severely affected patients. As reviewed by Shlobin and Nathan, 87 lung transplantation in sarcoidosis patients might be underutilized. Importantly, despite reported recurrences of sarcoidosis after transplantation, the mortality rate is comparable to that of other conditions. 87 Newer treatment options, namely the antifibrotic agent, pirfenidone, and the multikinase inhibitor, nintedanib, yielded promising results in IPF (reviewed by Tzouvelekis et al 88 ), but have not been investigated in advanced sarcoidosis.
SUMMARY
Sarcoidosis is a heterogenous disease with a variable clinical picture and disease course. Clinical, laboratory, and functional evaluation has to be comprehensive in patients not responding to standard therapy, and other causes (cardiac dyspnea, PH, infections) have to be excluded first before patients are labeled as "treatment-refractory."
We propose a new definition of refractory disease based on (1) the responsiveness to/tolerance of glucocorticoids; and (2) progressive pulmonary symptoms despite established therapeutic options.
In refractory cases, DMASD and biologicals can be used. MTX is preferred by most sarcoidologists; AZA and LEF are viable alternatives. The different advantages and disadvantages of each agent have to be discussed individually with the patient as none of these medications has been approved for use by the US FDA or the European Medicines Agency.
Third-line options include anti-TNF a-blockers. The first choice is infliximab because of 2 available double-blind placebo-controlled clinical trials; Adalimumab has also been used successfully in many patients with refractory disease. The reason as to why there are some agents of the same class (etanercept and golimumab) that do not seem to be equally effective is not convincingly explained until now.
In the future, patients with fibrotic sarcoid lung disease might benefit from newer drugs used in IPF, such as pirfenadine and nintedanib. These agents have not been studied in fibrotic sarcoidosis until now.
Lung transplantation is a viable option for the most severely affected patients and should be considered relatively early in the disease course of refractory patients. A multidisciplinary approach is required to identify optimal candidates for transplantation and ultimately improve outcomes.
Equally important in the management of patients with refractory sarcoidosis is the recognition and the appropriate treatment of complications, such as infections (aspergilloma, bacterial infections), bronchiectasis, bronchial stenosis, and PH.
